title: [Pharmacogenetic features of the effect of metformin in patients with coronary heart disease in the presence of metabolic syndrome and type 2 diabetes mellitus in terms of PPAR-gamma2 gene polymorphism].
abstract: OBJECTIVE
  To define the pharmacogenetic features of the effect of metformin in coronary heart disease (CHD) patients with metabolic syndrome (MS) or type 2 diabetes mellitus (T2DM), by taking into consideration PPAR-gamma2 Pro1 2Ala polymorphism.
  
  
  METHODS
  Twenty-four men with CHD and MS and 28 men with CHD and T2DM were examined. The effect of metformin as a short course in combination therapy was evaluated. A population control group consisted of 46 apparently healthy men. The genetic PPRA-gamma2 Pro12Ala polymorphism was studied. A number of indicators (total cholesterol (TC), high-density lipoprotein cholesterol, total lipids, triglycerides, beta-lipoproteins, glycated hemoglobin, C-peptide) and proinflammatory markers, such as interleukin (IL)-1beta, IL-6, IL-8, and tumor necrosis factor-alpha (TNF-alpha) were determined in the blood.
  
  
  RESULTS
  Analysis of the frequencies of Pro and Ala alleles indicated a decrease in the latter in CHD patients with T2DM. The CHD and MS patients who carried the Pro allele showed a significant metformin-induced reduction in weight, waist circumference, body mass index, and concentrations of TC, C-peptide, and cytokines, such IL-1beta, IL-6, IL-8, and TNF-alpha.
  
  
  CONCLUSIONS
  Metformin exhibits a high therapeutic efficacy in patients with CHD in the presence of T2DM or MS who have the Pro/Pro genotype, which is of interest in terms of pharmacogenetics and calls for further investigation.
authors.forename: A V
authors.initials: AV
authors.lastname: Lavrenko
authors.forename: O A
authors.initials: OA
authors.lastname: Shlykova
authors.forename: L A
authors.initials: LA
authors.lastname: Kutsenko
authors.forename: T V
authors.initials: TV
authors.lastname: Mamontova
authors.forename: I P
authors.initials: IP
authors.lastname: Kaĭdashev
mesh_terms: D000368:Aged; D000483:Alleles; D001835:Body Weight / Q000187:drug effects; D016022:Case-Control Studies; D003327:Coronary Disease / Q000188:drug therapy*; D016207:Cytokines / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005838:Genotype; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology; D008055:Lipids / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000188:drug therapy*; D008687:Metformin / Q000008:administration & dosage / Q000494:pharmacology*; D008875:Middle Aged; D047495:PPAR gamma / Q000235:genetics*; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic
chemical_list: D016207:Cytokines; D007004:Hypoglycemic Agents; D008055:Lipids; D047495:PPAR gamma; D008687:Metformin